gptkbp:instance_of
|
gptkb:pharmaceuticals
|
gptkbp:administered_by
|
oral tablet
|
gptkbp:approves
|
gptkb:2011
gptkb:FDA
|
gptkbp:brand
|
gptkb:Zelboraf
|
gptkbp:chemical_formula
|
C23 H27 Cl F2 N2 O2 S
|
gptkbp:class
|
gptkb:Atom
|
gptkbp:clinical_trial
|
gptkb:BRIM-2
gptkb:BRIM-3
gptkb:BRIM-4
Phase III
BRIM-1
|
gptkbp:clinical_use
|
advanced melanoma
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to vemurafenib
|
gptkbp:discovered_by
|
gptkb:Genentech
|
gptkbp:dosage_form
|
gptkb:tablet
|
gptkbp:drug_interactions
|
CYP3 A4 inducers
CYP2 C9 inhibitors
|
https://www.w3.org/2000/01/rdf-schema#label
|
vemurafenib
|
gptkbp:indication
|
gptkb:BRAF_V600_E_mutation-positive_melanoma
|
gptkbp:invention
|
patented
|
gptkbp:lifespan
|
57 hours
|
gptkbp:marketed_as
|
gptkb:Roche
|
gptkbp:mechanism_of_action
|
BRAF inhibitor
|
gptkbp:metabolism
|
liver
|
gptkbp:pharmacokinetics
|
highly protein-bound
inhibits cell proliferation
induces apoptosis
|
gptkbp:production_status
|
marketed
|
gptkbp:research_areas
|
oncology
pharmacogenomics
|
gptkbp:route_of_administration
|
oral
|
gptkbp:safety_measures
|
hepatotoxicity
QT prolongation
ocular toxicity
risk of new malignancies
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
headache
nausea
vomiting
diarrhea
joint pain
constipation
skin rash
hypoglycemia
photosensitivity
cardiac arrhythmias
alopecia
hyperglycemia
thromboembolism
hypersensitivity reactions
elevated liver enzymes
musculoskeletal pain
pruritus
|
gptkbp:targets
|
gptkb:BRAF_V600_E_mutation
|
gptkbp:used_for
|
treatment of melanoma
|
gptkbp:bfsParent
|
gptkb:Cotellic
gptkb:Zelboraf
|
gptkbp:bfsLayer
|
6
|